Quantcast
Last updated on April 23, 2014 at 15:59 EDT

Latest Motor neuron disease Stories

2012-05-01 02:26:26

The Month of May is Recognized Nationally to Heighten Awareness of the Effects of the Neuromuscular Disease TUCSON, Ariz., May 1, 2012 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association marks the 21st annual ALS Awareness Month in May by featuring individuals living with the disease in a monthlong series of online profiles called "ALS: Anyone's Life Story®." Local activities, including ALS seminars, special support group programs, and ALS Awareness-themed baseball games...

2012-04-30 06:24:42

CHICAGO, April 30, 2012 /PRNewswire/ -- Today Ronald L. Chez, owner of 9.2% of Repligen Corporation (Nasdaq: RGEN), issued the following statement: "As a result of my constructive recent conversation with Karen Dawes, Chairperson of Repligen's Board, I plan to discuss my proxy proposal regarding the reduction from 50% to 20% of outstanding shares, to call a special meeting." In addition, "I plan to discuss strategic alternatives for Repligen in light of the positive Phase 1 results of 3039...

2012-04-24 22:21:07

Crucial clinical trial support provided by MDA TUCSON, Ariz., April 25, 2012 /PRNewswire-USNewswire/ -- Repligen Corp., in Waltham, Mass., announced today that its experimental drug RG3039, designed to treat spinal muscular atrophy (SMA), was safe and well-tolerated in a phase 1 clinical trial. In addition, data suggested that the drug reached and acted on its biological target, an enzyme called DcpS. (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO) The trial of RG3039...

2012-04-23 06:24:34

The annual three day, 270 mile bike ride continues its commitment to fund research to end ALS CAMBRIDGE, Mass., April 23, 2012 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) Tri-State Trek is celebrating its 10th anniversary this year. A three-day, 270 mile bike ride from Boston to Greenwich, CT, the Trek raises money and awareness to end amyotrophic lateral sclerosis (ALS), better known as Lou Gehrig's disease. (Logo:...

2012-04-11 14:59:04

An abnormally low level of a protein in certain nerve cells is linked to movement problems that characterize the deadly childhood disorder spinal muscular atrophy, new research in animals suggests. Spinal muscular atrophy, or SMA, is caused when a child´s motor neurons — nerve cells that send signals from the spinal cord to muscles — produce insufficient amounts of what is called survival motor neuron protein, or SMN. This causes motor neurons to die, leading to muscle...

2012-04-02 06:27:38

Tournament Proceeds to Benefit Research into Treatments for ALS, Lou Gehrig's Disease CAMBRIDGE, Mass., April 2, 2012 /PRNewswire-USNewswire/ -- The Young Faces of ALS Campaign (YFALS) announced its second annual "National Corntoss Challenge" fundraising event occurring in multiple cities this May and June in support of research toward an effective treatment for ALS, better known as Lou Gehrig's disease. This is a charity tournament where thousands of participants in cities from coast to...

2012-03-29 02:39:55

Neuralstem, Inc. (NYSE Amex: CUR) announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) to receive its stem cells were reported online in the peer-reviewed publication, Stem Cells, on March 13th. "Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients" reports that one patient has shown improvement in his clinical status, even though researchers caution that the study...

2012-03-28 02:25:50

ROCKVILLE, Md., March 28, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) to receive its stem cells were reported online in the peer-reviewed publication, STEM CELLS, on March 13th. "Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients" (http://www.ncbi.nlm.nih.gov/pubmed/22415942.1) reports that one...

2012-03-07 11:20:50

Scientists from the Ottawa Hospital Research Institute and the University of Ottawa have discovered that a drug called fasudil can extend the average lifespan of mice with Spinal muscular atrophy from 30.5 days to more than 300 days Scientists from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) have discovered that a drug called fasudil can extend the average lifespan of mice with Spinal muscular atrophy (SMA) from 30.5 days to more than 300 days. The...

2012-03-07 11:16:28

Spinal muscular atrophy (SMA) is an incurable, and progressive, disease caused by an inheritable defect in the gene SMN1. Depending on the severity of the mutation it can result in the loss of spinal cord motor neurons, muscle wasting (atrophy) and even death of an affected child. A new study published in Biomed Central's open access journal BMC Medicine shows that Fasudil, a ROCK inhibitor, can improve both the size of muscle fibers and their connection to motor neurons. Fasudil also...